Compare MOD & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | GH |
|---|---|---|
| Founded | 1916 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 13.3B |
| IPO Year | 1995 | 2018 |
| Metric | MOD | GH |
|---|---|---|
| Price | $200.27 | $91.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 20 |
| Target Price | ★ $212.67 | $117.80 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.87 | 6.74 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $1,352,500,000.00 | $982,021,000.00 |
| Revenue This Year | $22.59 | $33.40 |
| Revenue Next Year | $21.82 | $28.55 |
| P/E Ratio | $206.12 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $64.79 | $36.36 |
| 52 Week High | $243.80 | $120.74 |
| Indicator | MOD | GH |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 34.70 |
| Support Level | $125.19 | $90.44 |
| Resistance Level | $239.41 | $114.53 |
| Average True Range (ATR) | 13.40 | 5.45 |
| MACD | -6.46 | -0.72 |
| Stochastic Oscillator | 27.69 | 11.56 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.